New drug switch for young transplant patients shows promise
NCT ID NCT01294020
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 27 times
Summary
This study involved 81 children who had received an organ transplant (like kidney, liver, or heart) and were taking a standard anti-rejection drug called Prograf. Researchers wanted to see if switching to a longer-acting version called Advagraf was safe and worked just as well. The children were followed for one year, and some continued long-term follow-up to monitor their health and the drug's effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site BE21
Brussels, 1020, Belgium
-
Site BE22
Brussels, 1200, Belgium
-
Site CZ42
Prague, 150 06, Czechia
-
Site DE41
Heidelberg, 69120, Germany
-
Site FR31
Paris, 75743, France
-
Site FR32
Paris, 75743, France
-
Site FR33
Paris, 75908, France
-
Site FR34
Bron, 69677, France
-
Site FR35
Bron, 69677, France
-
Site GB61
Manchester, M27 4HA, United Kingdom
-
Site GB62
Birmingham, B4 6NH, United Kingdom
-
Site GB64
London, WC1 3JH, United Kingdom
-
Site IT74
Bergamo, 24127, Italy
-
Site IT75
Palermo, 90127, Italy
-
Site PL51
Warsaw, 04-730, Poland
-
Site PL52
Warsaw, 04-730, Poland
Conditions
Explore the condition pages connected to this study.